Sein métastatique HER2+
DESTINY Breast 09
Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
Paris, Saint-Cloud
JEAN-YVES PIERGA, ETIENNE BRAIN